Part 1 Water Soluble Vitamins

1
74
General Information
Chemistry
Thiamin (vitamin B
1
) is a relatively heat- and acid-stable, water-soluble compound, containing a
pyrimidine and a thiazole nucleus linked by a methylene bridge. Derivatives of thiamin include the
mono-, pyro- and triphosphate forms and the synthetic hydrochloride and slightly less water-soluble
mononitrate salt. Synthetic non water-soluble derivatives of thiamin are available but these are not used
in food supplements.
Occurrence in food, food supplements and medicines
Foods providing rich sources of thiamin include unrefined grain products, meat products, vegetables,
dairy products, legumes, fruits and eggs. In the UK there is mandatory fortification of white and brown
flour with thiamin, to a level of not less than 0.24 mg/100g flour, to replace losses during production;
thus, cereal products are also a rich source of thiamin.
Mononitrate or hydrochloride derivatives of thiamin are present in multi-constituent medicinal products
for the prevention (dose 1 5 mg daily) or treatment (dose 10 35 mg daily) of nutrient deficiencies.
Supplements containing thiamin alone are also available (daily doses up to 300 mg).
Recommended amounts
Body stores of thiamin are limited and a regular intake is necessary. Thiamin requirement is related to
energy consumption. The RNI for adults and children 1 year is 0.4 mg/1000 kcal and 0.3 mg/1000
kcal in infants (COMA, 1991). Assuming food intakes of 2000 kcal/day and 20% losses through cooking,
this can be estimated to be 1.4 and 1 mg/day for adult males and females respectively. In pregnancy and
lactation, thiamin requirement increases to approximately 1.6 1.8 mg/day.
Analysis of tissue levels and thiamin status
Thiamin status may be assessed by measurement of thiamin levels in blood or by urinary excretion,
before and after loading. Erythrocyte transketolase (ETK) activity or its activation coefficient (ATK-AC) in
haemolysed red blood cells is a functional measure of thiamin status.
Brief overview of non-nutritional beneficial effects
No reports of non-nutritional beneficial effects have been identified. Established therapeutic uses of
thiamin supplements are largely related to the treatment or prophylaxis of deficiency. The effects of
thiamin on spasmodic dysmenorrhoea, exercise performance, ventricular function, Alzheimers disease,
and leg cramps during pregnancy have been investigated, with inconclusive results.
Risk Assessment Thiamin (Vitamin B
1
)
1
Function
Thiamin pyrophosphate (TPP) is a co-enzyme in several enzymatic reactions. TPP may also have a non-
co-enzymic function during stimulation of neuronal cells and other excitable tissues, such as skeletal
muscle.
Deficiency
The biological half-life of thiamin is approximately 10 20 days and marginal deficiency can develop
quite rapidly. Symptoms of sub-clinical deficiency include headache, tiredness, anorexia and muscle
wasting. A regular daily thiamin intake of 0.2 mg/1000 kcal results in clinical deficiency and the disease
known as beriberi, which affects the cardiovascular and nervous systems. Thiamin deficiency can result in
a disorder of the central nervous system known as Wernickes encephalopathy, characterised by
confusion, ataxia and coma. This condition is sometimes accompanied by a syndrome known as Korsakoff
psychosis. Both conditions are typically found in alcoholics and co-exist in Wernicke-Korsakoff syndrome.
In developed countries, most cases of thiamin deficiency are associated with chronic alcoholism where
dietary intake of the vitamin may be low and absorption and utilisation impaired.
Thiamin deficiency may also be involved in foetal alcohol syndrome, characterised by growth retardation,
psychomotor abnormalities and congenital malformations, in the offspring of alcoholic mothers.
Interactions
Alcohol can impair the uptake and utilisation of thiamin and these effects may contribute to the
prevalence of thiamin deficiency in alcoholics. Alcohol also reduces cellular thiamin diphosphokinase
activity. Thiamin is an acetylcholine antagonist, and thus may enhance the effect of neuromuscular
blocking agents. 5-Fluorouracil appears to be antagonistic to thiamin, possibly through competition for
phosphorylation, which is required by both entities for their activation.
Absorption and bioavailability
Thiamin in food appears to be highly available for absorption. Absorption of thiamin hydrochloride and
other water-soluble forms of thiamin is dose-dependent. At physiological concentrations, intestinal
uptake occurs mainly via a carrier-mediated transport mechanism. However, this process is saturable and
at higher concentrations, uptake is predominately by slower passive diffusion.
Distribution and metabolism
In the blood and tissues, thiamin is present as the free form and mono-, di- (pyro) and triphosphorylated
forms, which are interconvertible. Free and phosphorylated forms are transported within the
erythrocytes, but plasma and cerebrospinal fluid contain only the free and monophosphorylated forms.
Within the tissues, most thiamin present is converted to the pyrophosphate form. Liver contains the
highest concentration of thiamin. Catabolic metabolism amounts to approximately 1 mg/day, and most
of this occurs in the liver. The mean thiamin content of human breast milk in the UK has been reported
to be 0.16 mg/L.
Excretion
Thiamin metabolites and thiamin in excess of requirements are excreted in the urine. The level of
unchanged thiamin in the urine increases as intake increases.
Expert Group on Vitamins and Minerals 2003
75
1
Part 1 Water Soluble Vitamins
1
Toxicity
Human data
The oral toxicity of thiamin and thiamin derivatives in humans is generally considered very low. Most
reports of adverse effects with exposure to thiamin follow parenteral nutrition. High oral doses of
thiamin hydrochloride ( 7000 mg) may cause headache, nausea, irritability, insomnia, rapid pulse and
weakness. These symptoms are relieved following cessation of treatment or reduction of dose. There
have been a very small number of reported adverse effects following lower doses from case reports.
Three case reports concerned women, one who experienced muscle tremor, rapid pulse and nervous
hyperirritability after taking daily doses of thiamin hydrochloride, reported to be 17 mg/day
14
. In another
case, a patient suffered an anaphylactic reaction and subsequently died following a single oral dose of
100 mg thiamin 2 months after repeatedly taking 100 mg thiamin per day for a period of 15 days. One
patient with thiamin-related contact dermatitis experienced an exacerbation of eczema following
experimental provocation with an oral dose of 200 mg thiamin. A fourth case-report involved a young
man who contracted allergic encephalitis following an oral dose of thiamin (the amount and form are
unclear).
No evidence has been identified on reproductive effects of thiamin or thiamin derivatives in humans.
Supplementation trials
In a supplementation study, one isolated individual, who had earlier received parenteral thiamin
hydrochloride, experienced nausea and insomnia following a daily dose of 200 mg thiamin
hydrochloride per day for less than a week. Symptoms resolved when the dose was halved.
Animal data
The animal toxicity database is limited. Thiamin is of low acute toxicity but single oral doses of 3000-
5000 mg/kg bw thiamin/thiamin hydrochloride in rats and mice are lethal. Thiamin nitrate is even less
acutely toxic, with no adverse effects being reported in mice following a single oral dose of 5000
mg/kg bw. There is an absence of chronic and sub-chronic data for high-dose exposure to the water-
soluble thiamin derivatives.
Carcinogenicity and genotoxicity
There has been no study on the carcinogenicity of thiamin. Thiamin hydrochloride has been shown to
be non-mutagenic in a range of bacterial mutagenicity and in vitro chromosomal aberration tests.
Genetic variations
There are no known genetic variations resulting in increased susceptibility to thiamine toxicity.
76
1
15
It is noted that a dose of 17 mg would have been inconsistent with the rate of urinary and likely faecal excretion quoted within the original article. It is suggested,
therefore, that this was a text error within the article that should have read 17 g, equivalent to 17,000 mg.
Mechanisms of toxicity
No mechanisms of toxicity have been identified.
Dose-response characterisation
No data have been identified.
Vulnerable groups
No vulnerable groups have been identified; however, the clinical trials indicate that there is a possibility
that a very small number of people may be particularly sensitive (allergic) to thiamin.
Studies of particular importance in the risk assessment
(For full review see http://www.food.gov.uk/science/ouradvisors/vitandmin/evmpapers or the
enclosed CD).
Human data
Mills, 1941
Thiamin-associated toxicity was reported in a 47 year old woman who had been taking 10,000 mg
thiamin hydrochloride daily for 2
1
/
2
weeks (presumably by the oral route, although this is unclear).
Symptoms were reported to resemble those of over-dosage of thyroid extract: headache, increased
irritability, insomnia, rapid pulse, weakness and trembling. Symptoms disappeared within 2 days
following cessation of treatment but recurred 4
1
/
2
weeks after the patient resumed a dose of 5 mg per
day
16
. Again, prompt relief soon followed cessation of intake. In the same report, Mills described
symptoms similar to those of thyroid hyperactivity, with fine and coarse muscle tremor, rapid pulse and
nervous hyperirritability in a young woman receiving an average of 17 mg thiamin hydrochloride per day
(again, this was presumed to be by mouth but this was not explicit)
17
. The woman was said to be
excreting 12 mg/day in her urine and passing stools smelling strongly of thiamin.
Meador et al., 1993
This was a study conducted in 17 Alzheimers patients (9 males and 8 females), mean age 69 years, to
assess possible beneficial effects of thiamin supplementation. Patients were treated with graduated
doses of thiamin hydrochloride, up to 6000-8000 mg/day, for 5-6 months. Subjects were reported to
have tolerated the doses well without weakness or other side effects, with the exception of two
subjects who developed nausea and indigestion at dose levels of 7000 and 7500 mg/day. However,
these individuals were subsequently returned to their own previously highest tolerated doses (6500 and
7000 mg/day) without side effects. The study was limited in that there were small numbers involved
and that 8/17 subjects suffered significant mental impairment on objective mental tests, so that any
effects may have been undereported.
Expert Group on Vitamins and Minerals 2003
16
The Mills report states 5 mg/day. However, when citing the Mills data, Iber et al. (1982) state 5 g/day.
17
The dose reported here as 17 mg is inconsistent with the quoted rate of urinary and likely faecal excretion and suggests that this is a text error within the Mills
report that should read 17 g. Such an error would be consistent with an earlier error within the same report, indicated by Iber et al. (see notes 15 and 16).
77
1
Part 1 Water Soluble Vitamins
1
Gokhale, 1996
A randomised double-blind placebo-controlled study was carried out in 556 females (aged 12-21 years)
from 14 schools and hostels in India, suffering from moderate to severe spasmodic dysmenorrhoea. The
thiamin status of the participants is unclear. A daily oral dose of 100 mg of thiamin hydrochloride was
given for 90 days followed by placebo for 60 days or vice versa. No adverse effects were reported.
Animal data
Molitor, 1942
The lethal dose for thiamin in mice was reported to be 100 mg (approximately 5000 mg/kg bw,
assuming a bodyweight of 20 g).
Leuschner, 1992
As a preliminary test to determine a maximum tolerated dose for an investigation into
the antinociceptive properties of thiamin, no toxic effects were observed in female NMRI mice (weight,
21 28 g) when administered oral doses of thiamin nitrate in 0.8% aqueous hydroxypropyl
methylcellulose gel at doses up to 5000 mg/kg bw. The number of animals tested was not stated.
Exposure assessment
Total exposure/intake:
Food Mean: 1.50 mg/day (from 1986/87 NDNS)
97.5th percentile: 2.6 mg/day
Supplements up to 300 mg/day (OTC, 2001)
Estimated maximum intake: 2.6 + 300 = 303 mg/day
No potential high intake groups have been identified.
Risk assessment
Thiamin present in food is efficiently absorbed. However, water-soluble supplements, such as thiamin
hydrochloride and thiamin mononitrate, are poorly absorbed due to saturation of transport mechanisms.
It is generally accepted that ingested thiamin has a very low toxicity in humans. Most data are either in
the form of case reports of possible thiamin-associated adverse effects or from thiamin
supplementation studies designed primarily to investigate potential beneficial effects. The latter do not
always specifically report an absence of adverse effect.
The limited amount of human data indicates that adverse effects are generally CNS-related and occur
only at very high doses. A small number of individuals may show an allergic response to lower doses,
78
1
but reports of these lower dose-related events are rare. It is possible that this sub-population may be
the same sub-group that is susceptible to adverse effects, e.g. anaphylaxis etc, following parenteral
administration of thiamin.
The animal database is also very limited. A lethal dose of thiamin in rodents is preceded by CNS effects
such as shock, muscle tremor, convulsions, respiratory disturbance and collapse, symptoms which are
similar to acute thiamin toxicity in humans.
ESTABLISHMENT OF GUIDANCE LEVEL
There are insufficient data to establish a Safe Upper Level for thiamin. The oral toxicity of thiamin and
thiamin derivatives in humans is generally considered to be very low. Most available documented data
are either in the form of case reports of possible thiamin-associated adverse effects or from thiamin
supplementation studies designed primarily to investigate potential beneficial effects. The latter
generally involve the use of the synthetic non-water soluble derivatives (not included in this review and
not currently found in dietary supplements) and do not always specifically report an absence of
adverse effect. Reports of thiamin-associated toxicity in humans are rare and most relate to incidents
following parenteral administration of the vitamin. High doses ( 5000 mg) of thiamin hydrochloride
may cause headache, nausea, irritability, insomnia, rapid pulse and weakness; these symptoms are
relieved following cessation of treatment or reduction of dose. There have been a very small number of
reported adverse effects following lower doses. These comprise four case reports and one isolated
individual taking part in a supplementation study.
No specific toxic effects of thiamin ingestion by humans have been identified. However, there is a
paucity of large controlled human supplementation studies. Significant adverse effects have not been
noted with the water-soluble forms of thiamin used in dietary supplements. These forms are poorly
absorbed at high doses, which further restricts their toxicity.
One human supplementation study (Meador et al., 1993) reported that graduated doses of thiamin
hydrochloride, up to 6000-8000 mg/day for 5-6 months, caused no adverse effects in a very small
group of patients. These subjects were reported to have tolerated the doses well, without weakness or
other side effects, with the exception of two subjects (out of seventeen) who developed nausea and
indigestion at doses of 7000 7500 mg. The study may well have under-reported side effects since half
of the subjects were suffering from significant mental impairment on objective measures. From the
available database, it appears that higher doses of thiamin ( 7000 mg) may be associated with
headache, nausea, irritability, insomnia, rapid pulse and weakness.
In a randomised double-blind placebo-controlled study by Gokhale et al. (1996), a daily oral dose of 100
mg thiamin hydrochloride (for sixty or ninety days) was given to 556 young females (12 21 years). No
adverse effects were reported. The thiamin status of the participants is unclear. Based on this study, a
level of 100 mg/day (equivalent to 1.7 mg/kg supplemental thiamin for a 60 kg adult) of supplemental
thiamin would not be expected to result in adverse effects. No uncertainty factor has been applied
since this guidance is based on human data with large numbers of subjects and no hazard has been
identified from other studies. This level is for guidance only and is applicable to the water-soluble forms
of thiamin only. It should be noted that the applicability of the study, which was conducted in young
women, to the general population is uncertain and the possibility of rare hypersensitivity reactions
cannot be excluded.
Expert Group on Vitamins and Minerals 2003
79
1
Part 1 Water Soluble Vitamins
1
References
COMA (1991). Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report
of the Panel on Dietary Reference Values, Committee on Medical Aspects of Food and Nutrition Policy.
HMSO, London.
Gokhale, LB (1996). Curative treatment of primary (spasmodic) dysmenorrhea. Indian Journal of Medical
Research 103, 227-231.
Iber, F.L., Blass, J.P., Brin, M., Leevy, C.M. (1982). Thiamin in the elderly relation to alcoholism and to
neurological degenerative disease. American Journal of Clinical Nutrition 36, 1067-1082.
Leuschner, J. (1992). Antinociceptive properties of thiamin, pyridoxine and cyanocobalamin following
repeated oral administration to mice. Arzneimittel-Forschung 42, 114-115.
Meador, K., Loring, D., Nichols, M., Zamrini, E., Rivner, M., Posas, H., Thompson, E., Moore, E. (1993).
Preliminary finding of a high dose thiamin in dementia of Alzheimers type. Journal of Geriatric
Psychiatry and Neurology 6, 222-229.
Mills, C.A. (1941). Thiamin overdosage and toxicity. Journal of the American Medical Association 116, 2101.
Molitor, H. (1942). Vitamins as pharmacological agents. Federation Proceedings 1, 309.
OTC (2001). OTC Directory 2001-2002, Proprietary Association of Great Britain.
80
1